Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data

被引:31
作者
Pavelic, Antun R. [1 ]
Woeber, Christian [2 ,3 ]
Riederer, Franz [1 ,4 ]
Zebenholzer, Karin [2 ,3 ]
机构
[1] Hietzing Hosp, Dept Neurol, A-1130 Vienna, Austria
[2] Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, A-1090 Vienna, Austria
[4] Univ Zurich, Fac Med, CH-8032 Zurich, Switzerland
关键词
real-world; erenumab; galcanezumab; fremanezumab; eptinezumab; pharmacoepidemiology; effectiveness; tolerability; safety; treatment pause; switching; PREVENTIVE TREATMENT; SUBGROUP ANALYSIS; DOUBLE-BLIND; MEDICATION OVERUSE; CGRP ANTIBODY; ERENUMAB; SAFETY; FREMANEZUMAB; GALCANEZUMAB; MULTICENTER;
D O I
10.3390/cells12010143
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs.
引用
收藏
页数:21
相关论文
共 175 条
[51]   Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine [J].
Driessen, Maurice T. ;
Cohen, Joshua M. ;
Thompson, Stephen F. ;
Patterson-Lomba, Oscar ;
Seminerio, Michael J. ;
Carr, Karen ;
Totev, Todor, I ;
Sun, Rochelle ;
Yim, Erica ;
Mu, Fan ;
Ayyagari, Rajeev .
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
[52]   Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study [J].
Driessen, Maurice T. ;
Cohen, Joshua M. ;
Patterson-Lomba, Oscar ;
Thompson, Stephen F. ;
Seminerio, Michael ;
Carr, Karen ;
Totev, Todor, I ;
Sun, Rochelle ;
Yim, Erica ;
Mu, Fan ;
Ayyagari, Rajeev .
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
[53]   Inhibitory effect of BIBN4096BS, CGRP8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery [J].
Edvinsson, L. ;
Nilsson, E. ;
Jansen-Olesen, I. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 150 (05) :633-640
[54]   Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries [J].
Edvinsson, Lars ;
Chan, Kayi Y. ;
Eftekhari, Sajedeh ;
Nilsson, Elisabeth ;
de Vries, Rene ;
Saveland, Hans ;
Dirven, Clemens M. F. ;
Danser, A. H. Jan ;
MaassenVanDenBrink, Antoinette .
CEPHALALGIA, 2010, 30 (10) :1233-1240
[55]   Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Quebec, Eastern Canada [J].
Eghtesadi, Marzieh ;
Leroux, Elizabeth ;
Page, Gabrielle .
CLINICAL DRUG INVESTIGATION, 2021, 41 (08) :733-739
[56]   Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists [J].
Evans, Randolph W. .
HEADACHE, 2019, 59 (08) :1360-1364
[57]   Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers [J].
Faust, Elizabeth ;
Pivneva, Irina ;
Yang, Karen ;
Betts, Keith A. ;
Ahmed, Zubair ;
Joshi, Shivang ;
Hogan, Rebecca ;
Blumenfeld, Andrew ;
Schim, Jack ;
Feoktistov, Alexander ;
Carnes, Kenneth ;
Bensink, Mark ;
Wu, Eric Q. ;
Chou, Denise E. ;
Chandler, David .
NEUROLOGY AND THERAPY, 2021, 10 (01) :293-306
[58]   Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial [J].
Ferrari, Michel D. ;
Diener, Hans Christoph ;
Ning, Xiaoping ;
Galic, Maja ;
Cohen, Joshua M. ;
Yang, Ronghua ;
Mueller, Matthias ;
Ahn, Andrew H. ;
Schwartz, Yael Carmeli ;
Grozinski-Wolff, Melissa ;
Janka, Lindsay ;
Ashina, Messoud .
LANCET, 2019, 394 (10203) :1030-1040
[59]   Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment [J].
Fofi, Luisa ;
Altamura, Claudia ;
Fiorentini, Giulia ;
Brunelli, Nicoletta ;
Marcosano, Marilena ;
Barbanti, Piero ;
Vernieri, Fabrizio .
HEADACHE, 2022, 62 (09) :1143-1147
[60]   Erenumab during pregnancy: a case report in a patient with chronic migraine [J].
Fofi, Luisa ;
Egeo, Gabriella ;
Aurilia, Cinzia ;
Barbanti, Piero .
NEUROLOGICAL SCIENCES, 2021, 42 (05) :2145-2146